Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we predict the path of chronic skin disease?

NCT ID NCT05928169

Knowledge-focused Sponsor: University Hospital Schleswig-Holstein Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 28, 2026 · Last updated Aug 28, 2026

Summary

This study follows 1,000 people with chronic inflammatory skin diseases, such as eczema, psoriasis, and rosacea, over time. Researchers will collect detailed clinical data and biological samples to see which factors correlate with disease activity and progression. The goal is to identify markers that could help predict patient subgroups and guide treatment decisions in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
No specific drug or intervention is being tested. This is an observational study that follows patients receiving routine care.
What this could lead to
If successful, this could identify biological and clinical markers that help doctors predict how a patient's skin disease will progress and choose the most effective treatment.
What could go wrong
This is an observational study, so it cannot prove cause and effect. The findings may not lead to immediate clinical changes, and the long follow-up may face participant dropout.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2023

Expected to finish

Dec 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with chronic inflammatory skin disease Healthy control individuals

Ages

0 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * dermatologist-diagnosed inflammatory skin disease * informed consent Exclusion Criteria: * subject and/or the legal guardians are not able to give written informed consent * pregnant and breastfeeding women * concurrent participation in a clinical trial * use of systemic immunosuppressive therapy or phototherapy during the last 4 weeks or receipt of biologics therapy (e.g. dupilumab, tralokinumab) within the last 3 months * treatment of the target skin areas with topical corticosteroids, calcineurin inhibitors or emollients 24 hours before sample collection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia areata are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia areata atopic eczema cutaneous lupus erythematosus hidradenitis suppurativa lichen planus prurigo nodularis psoriasis rosacea vitiligo

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia areata Atopic dermatitis Cutaneous lupus Hidradenitis suppurativa Lichen planus Prurigo nodularis Psoriasis Rosacea

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Dermatology and Allergy, University Hospital Schleswig-Holstein

    RECRUITING

    Kiel, 24105, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.